| Decitabine and sorafenib therapy in FLT-3 ITD-mutant acute myeloid leukemia MR Muppidi, S Portwood, EA Griffiths, JE Thompson, LA Ford, CW Freyer, ... Clinical Lymphoma Myeloma and Leukemia 15, S73-S79, 2015 | 56 | 2015 |
| Interaction between voriconazole and glimepiride. MMR Shobha JC J Postgrad Med 56, 44-5, 2010 | 17 | 2010 |
| Immune checkpoint inhibitors in renal cell carcinoma MR Muppidi, S George MJH Life Sciences, 2015 | 15 | 2015 |
| Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment A Emadi, JE Karp Springer Publishing Company, 2017 | 8 | 2017 |
| Decitabine and sorafenib therapy in patients with FLT3-ITD mutant acute myeloid leukemia is associated with high response rates—a single institute experience MR Muppidi, EA Griffiths, JE Thompson, LA Ford, CW Freyer, M Wetzler, ... Blood 124 (21), 5284, 2014 | 4 | 2014 |
| Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG±M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior … A Przespolewski, MR Muppidi, CW Freyer, W Ji, TL Cronin, S Thota, ... Leukemia & Lymphoma 62 (7), 1778-1781, 2021 | 2 | 2021 |
| Rasburicase in treating tumor lysis syndrome: An umbrella review K Mahfooz, H Sohail, A Gvajaia, U Arif, D Grewal, MR Muppidi, V Vohra, ... Cancer Pathogenesis and Therapy 1 (04), 262-271, 2023 | 1 | 2023 |
| Severe pancytopenia after COVID-19 revealing a case of primary bone marrow diffuse large B cell lymphoma Y Kilani, H Sohail, CY Lim, A Payette, SAF Kamal, A Afzal, T Khan, ... The American Journal of Case Reports 23, e937500-1, 2022 | 1 | 2022 |
| CLAG±M (cladribine, cytarabine, granulocyte colony stimulating factor±mitoxantrone) Results in High Response Rates in Older Patients with Secondary and Relapsed/Refractory … MR Muppidi, CW Freyer, LA Ford, EP Ontiveros, JE Thompson, ... Blood 126 (23), 1341, 2015 | 1 | 2015 |
| Decitabine and sorafenib therapy in FLT3-ITD mutant acute myeloid leukemia-A case series MR Muppidi, EA Griffiths, JE Thompson, LA Ford, CW Freyer, M Wetzler, ... Clinical Lymphoma, Myeloma and Leukemia 15, S187, 2015 | 1 | 2015 |
| Prognostic factors in haemangioendotheliomas (HE): Analysis based on the surveillance, epidemiology, and end results (SEER) program MR Muppidi, J Vijayakumar, A Groman, K Salerno, V Francescutti, ... J Clin Oncol 32, 5S, 2014 | 1 | 2014 |
| Differences in Outcomes of Hemophagocytic Lymphohistiocytosis (HLH) Based on Etiology: A Five Year Nationwide Analysis A Kamal, S Vikash, F Vikash, MR Muppidi Blood 142, 1166, 2023 | | 2023 |
| A Case of Amoxicillin-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (Dress) Syndrome Associated With Significant Reactive Hypereosinophilia (HE): A Case Report J Oh, A Singh, M Fonseca, M Muppidi Cureus 15 (7), 2023 | | 2023 |
| A survival analysis of sarcomatoid renal cell carcinoma (sRCC)-a single institute experience J Gaddy, S Kothari, M Muppidi, H Bakhribah, K Wang, S George BJU INTERNATIONAL 118, 25-25, 2016 | | 2016 |
| Factors predicting clinical outcome of induction hypomethylating agents in older patients with acute myeloid leukemia. N Ammannagari, MR Muppidi, LA Ford, EA Griffiths, E Ontiveros, ... Journal of Clinical Oncology 34 (15_suppl), 7037-7037, 2016 | | 2016 |
| Decitabine/idarubicin/sorafenib MR Muppidi Reactions 1584, 76-16, 2016 | | 2016 |
| COMPARISON OF ELECTRONIC CARESETS TO GUIDE VENOUS THROMBOEMBOLISM RISK ASSESSMENT L Verda, W Trick, A Sahni, A Saini, S Khanna, M Muppidi, S Borkowsky, ... JOURNAL OF GENERAL INTERNAL MEDICINE 27, S148-S148, 2012 | | 2012 |
| VTE Risk Assessment and Prophylaxis: The Reliability of Clinical Assessment by Medical Housestaff MR Muppidi, A Sahni, A Saini, S Khanna, L Verda, W Trick, S Borkowsky, ... Blood 118 (21), 4199, 2011 | | 2011 |
